ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)

Clinical Microbiology and Infection

Volumn 24, Issue , 2018, Pages S2-S9

  Fernandez Ruiz M ^a,b   Meije, Y ^c   Manuel, O ^d   Akan, H ^e   Carratala J ^b,f   Aguado, J M ^a,b   Delaloye, J ^d  

^a Universidad Complutense ^*  (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Hospital de Niños de Barcelona   (Spain)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e ANKARA UNIVERSITY   (Turkey)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Biological therapies; Infection; Monoclonal antibodies; Recommendations; Review; Small molecule inhibitors; Targeted therapies

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; IMMUNOGLOBULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PROTEASOME INHIBITOR; IMMUNOLOGIC FACTOR;

BIOLOGICAL THERAPY; CONSENSUS DEVELOPMENT; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EUROPE; HUMAN; INFECTION; INFECTION RISK; INTRACELLULAR SIGNALING; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; COMMUNICABLE DISEASE; DRUG THERAPY; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MOLECULAR LIBRARY; MOUSE; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; COMMUNICABLE DISEASES; CYTOKINES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; MICE; MOLECULAR TARGETED THERAPY; SMALL MOLECULE LIBRARIES;

EID: 85042562344     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2018.01.029     Document Type: Review

References (64)

1. Baddley, J.W., Cantini, F., Goletti, D., Gómez-Reino, J.J., Mylonakis, E., San-Juan, R., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect 24 (2018), S10–S20.
2. Winthrop, K.L., Mariette, X., Silva, J.T., Benamu, E., Calabrese, L.H., Dumusc, A., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 24 (2018), S21–S40.
3. Aguilar-Company, J., Fernández-Ruiz, M., García-Campelo, R., Garrido-Castro, A.C., Ruiz-Camps, I., ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways). Clin Microbiol Infect 24 (2018), S41–S52.
4. Reinwald, M., Silva, J.T., Mueller, N.J., Fortún, J., Garzoni, C., de Fijter, J.W., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways). Clin Microbiol Infect 24 (2018), S53–70.
5. Mikulska, M., Lanini, S., Gudiol, C., Drgona, L., Ippolito, G., Fernández-Ruiz, M., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 24 (2018), S71–S82.
6. Drgona, L., Gudiol, C., Lanini, S., Salzberger, B., Ippolito, G., Mikulska, M., ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 24 (2018), S83–S94.
7. Redelman-Sidi, G., Michielin, O., Cervera, C., Ribi, C., Aguado, J.M., Fernández-Ruiz, M., et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 24 (2018), S95–S107.
8. Valent, P., Groner, B., Schumacher, U., Superti-Furga, G., Busslinger, M., Kralovics, R., et al. Paul Ehrlich (1854–1915) and his contributions to the foundation and birth of translational medicine. J Innate Immun 8 (2016), 111–120.
9. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001), 1031–1037.
10. Maloney, D.G., Grillo-Lopez, A.J., White, C.A., Bodkin, D., Schilder, R.J., Neidhart, J.A., et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 (1997), 2188–2195.
11. Santos, R., Ursu, O., Gaulton, A., Bento, A.P., Donadi, R.S., Bologa, C.G., et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov 16 (2017), 19–34.
12. Naldini, L., Gene therapy returns to centre stage. Nature 526 (2015), 351–360.
13. Ribeil, J.A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., et al. Gene therapy in a patient with sickle cell disease. N Engl J Med 376 (2017), 848–855.
14. Dahlberg, C.I., Sarhan, D., Chrobok, M., Duru, A.D., Alici, E., Natural killer cell–based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity. Front Immunol, 6, 2015, 605.
15. Kim, S.S., Rait, A., Kim, E., Pirollo, K.F., Nishida, M., Farkas, N., et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano 8 (2014), 5494–5514.
16. Carruthers, K.H., Metzger, G., During, M.J., Muravlev, A., Wang, C., Kocak, E., Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models. Cancer Gene Ther 21 (2014), 434–440.
17. Albarakati, N., Abdel-Fatah, T.M., Doherty, R., Russell, R., Agarwal, D., Moseley, P., et al. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. Mol Oncol 9 (2015), 204–217.
18. Foreman, P.M., Friedman, G.K., Cassady, K.A., Markert, J.M., Oncolytic virotherapy for the treatment of malignant glioma. Neurotherapeutics 14 (2017), 333–344.
19. Amato, R.J., Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clin Genitourin Cancer 5 (2007), 422–426.
20. Nakamura, R.M., Monoclonal antibodies: methods and clinical laboratory applications. Clin Physiol Biochem 1 (1983), 160–172.
21. Bruggemann, M., Winter, G., Waldmann, H., Neuberger, M.S., The immunogenicity of chimeric antibodies. J Exp Med 170 (1989), 2153–2157.
22. Gussow, D., Seemann, G., Humanization of monoclonal antibodies. Methods Enzymol 203 (1991), 99–121.
23. Presta, L.G., Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58 (2006), 640–656.
24. World Health Organization, Programme on International Nonpropietary Names (INN), Revised monoclonal antibody nomenclature scheme. 2017 Available at: http://www.who.int/entity/medicines/services/inn/Revised_mAb_nomenclature_scheme.pdf.
25. Glennie, M.J., French, R.R., Cragg, M.S., Taylor, R.P., Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44 (2007), 3823–3837.
26. Singh, S., Kumar, N., Dwiwedi, P., Charan, J., Kaur, R., Sidhu, P., et al. Monoclonal antibodies: a review. Curr Clin Pharmacol, 2017 Aug 9, 10.2174/1574884712666170809124728 [Epub ahead of print], PMID: 28799485.
27. Nadler, L.M., Takvorian, T., Botnick, L., Bast, R.C., Finberg, R., Hellman, S., et al. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 2:8400 (1984), 427–431.
28. Oflazoglu, E., Audoly, L.P., Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2 (2010), 14–19.
29. Lim, S.H., Beers, S.A., French, R.R., Johnson, P.W., Glennie, M.J., Cragg, M.S., Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95 (2010), 135–143.
30. Zundorf, I., Dingermann, T., PEGylation—a well-proven strategy for the improvement of recombinant drugs. Pharmazie 69 (2014), 323–326.
31. Pasut, G., Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs 28:Suppl. 1 (2014), S15–S23.
32. Tolcher, A.W., Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol 27 (2016), 2168–2172.
33. Wolska-Washer, A., Robak, P., Smolewski, P., Robak, T., Emerging antibody–drug conjugates for treating lymphoid malignancies. Expert Opin Emerg Drugs 22 (2017), 259–273.
34. Liu, H., Saxena, A., Sidhu, S.S., Wu, D., Fc Engineering for developing therapeutic bispecific antibodies and novel scaffolds. Front Immunol, 8, 2017, 38.
35. Wilke, A.C., Gokbuget, N., Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Expert Opin Drug Saf 16 (2017), 1191–1202.
36. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B.J., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56 (1996), 100–104.
37. Dienstmann, R., Tabernero, J., BRAF as a target for cancer therapy. Anticancer Agents Med Chem 11 (2011), 285–295.
38. Lin, X., Qureshi, M.Z., Attar, R., Khalid, S., Tahir, F., Yaqub, A., et al. Targeting of BCR-ABL: lessons learned from BCR-ABL inhibition. Cell Mol Biol (Noisy-le-grand) 62 (2016), 129–137.
39. Cosgarea, I., Ritter, C., Becker, J.C., Schadendorf, D., Ugurel, S., Update on the clinical use of kinase inhibitors in melanoma. J Dtsch Dermatol Ges 15 (2017), 887–893.
40. Barrientos, J.C., Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco Targets Ther 9 (2016), 2945–2953.
41. Cheng, Y., Tian, H., Current development status of MEK inhibitors. Molecules, 22(10), 2017 Sep 26, 10.3390/molecules22101551 pii: E1551.
42. Dancey, J.E., Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16 (2002), 1101–1114.
43. Gadina, M., Hilton, D., Johnston, J.A., Morinobu, A., Lighvani, A., Zhou, Y.J., et al. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol 13 (2001), 363–373.
44. Rask-Andersen, M., Zhang, J., Fabbro, D., Schioth, H.B., Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci 35 (2014), 604–620.
45. van Erp, N.P., Gelderblom, H., Guchelaar, H.J., Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35 (2009), 692–706.
46. Shao, J., Markowitz, J.S., Bei, D., An, G., Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 103 (2014), 3810–3833.
47. Her, M., Kavanaugh, A., Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 137 (2016), 19–27.
48. Boyman, O., Comte, D., Spertini, F., Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 10 (2014), 612–627.
49. Salvana, E.M., Salata, R.A., Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 22 (2009), 274–290.
50. Qamar, N., Fuleihan, R.L., The hyper IgM syndromes. Clin Rev Allergy Immunol 46 (2014), 120–130.
51. Cabral-Marques, O., Klaver, S., Schimke, L.F., Ascendino, E.H., Khan, T.A., Pereira, P.V., et al. First report of the hyper-IgM syndrome registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes. J Clin Immunol 34 (2014), 146–156.
52. Huppler, A.R., Bishu, S., Gaffen, S.L., Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther, 14, 2012, 217.
53. Riera, R., Porfirio, G.J., Torloni, M.R., Alemtuzumab for multiple sclerosis. Cochrane Database Syst Rev, 4, 2016, CD011203.
54. Warner, J.L., Arnason, J.E., Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol 3 (2012), 375–389.
55. Del Castillo, M., Romero, F.A., Arguello, E., Kyi, C., Postow, M.A., Redelman-Sidi, G., The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63 (2016), 1490–1493.
56. Strangfeld, A., Eveslage, M., Schneider, M., Bergerhausen, H.J., Klopsch, T., Zink, A., et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis 70 (2011), 1914–1920.
57. Prestes, D.P., Arbona, E., Nevett-Fernandez, A., Woolley, A.E., Ho, V.T., Koo, S., et al. Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation. Clin Infect Dis 65 (2017), 510–513.
58. Naylor, K., Li, G., Vallejo, A.N., Lee, W.W., Koetz, K., Bryl, E., et al. The influence of age on T cell generation and TCR diversity. J Immunol 174 (2005), 7446–7452.
59. Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001), 1098–1104.
60. Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G., Nath, A., Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9 (2010), 438–446.
61. Carson, K.R., Newsome, S.D., Kim, E.J., Wagner-Johnston, N.D., von Geldern, G., Moskowitz, C.H., et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer 120 (2014), 2464–2471.
62. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V., Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006), 2275–2285.
63. Winthrop, K.L., Novosad, S.A., Baddley, J.W., Calabrese, L., Chiller, T., Polgreen, P., et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 74 (2015), 2107–2116.
64. Bryant, P.A., Baddley, J.W., Opportunistic infections in biological therapy, risk and prevention. Rheum Dis Clin North Am 43 (2017), 27–41.